Centre for Brain Aging and Neurodegenerative Disorders, Department of Neurology, University of Brescia, Italy.
Exp Gerontol. 2010 Jan;45(1):53-6. doi: 10.1016/j.exger.2009.08.004. Epub 2009 Aug 21.
A correct clinical diagnosis in the early stage of Alzheimer Disease (AD) is mandatory given the current available treatment with acetylcholine esterase inhibitors. Moreover, a early to preclinical diagnosis would allow to identify patients eligible for future disease-modifying therapies. In the last ten years, we have focused our attention on peripheral markers, evaluating the role of platelet Amyloid Precursor Protein (APP) forms as a reliable tool for AD diagnosis since preclinical stages. APP is the key player in AD pathogenesis, and platelets contain all the enzymatic machinery to its processing, thus being the ideal candidate where to study AD pathogenetic mechanisms. In this review, we summarise the published data regarding the usefulness of platelet APP form ratio in the diagnosis of early AD. Approaches combining APP form ratio along with neuroimaging markers show the promise to accurately identify AD, even in the pre-symptomatic stage.
鉴于目前可用的乙酰胆碱酯酶抑制剂治疗方法，在阿尔茨海默病（AD）的早期阶段进行正确的临床诊断是强制性的。此外，早期到临床前的诊断可以确定哪些患者有资格接受未来的疾病修饰疗法。在过去的十年中，我们一直专注于外周标志物，评估血小板淀粉样前体蛋白（APP）形式作为 AD 诊断的可靠工具的作用，因为它处于临床前阶段。APP 是 AD 发病机制中的关键因素，血小板包含其加工的所有酶学机制，因此是研究 AD 发病机制的理想候选者。在这篇综述中，我们总结了关于血小板 APP 形式比率在早期 AD 诊断中的有用性的已发表数据。结合 APP 形式比率和神经影像学标志物的方法有望准确识别 AD，即使在无症状阶段也是如此。
